Advertisement

Search Results

Advertisement



Your search for Margaret von Mehren, MD matches 5 pages

Showing 1 - 5


gastrointestinal cancer

Pivotal Study Reports Positive Findings in Fourth-Line Setting for Advanced GIST

In a late-breaking, oral presentation at the European Society for Medical Oncology (ESMO) 2019 Congress, Margaret von Mehren, MD, presented results from INVICTUS, a pivotal phase III clinical study of ripretinib in patients with advanced gastrointestinal stromal tumor (GIST).1 Ripretinib is an...

gastrointestinal cancer

Pivotal Phase III Study Evaluates Investigational TKI in Fourth-Line Setting for Advanced GIST

In a late-breaking, oral presentation at the ESMO Congress 2019, Margaret von Mehren, MD, presented results from ­INVICTUS, a pivotal phase III clinical trial of ripretinib in patients with advanced gastrointestinal stromal tumor (GIST).1 Ripretinib is an investigational tyrosine kinase inhibitor...

Fox Chase Cancer Center Announces 2018 Award Recipients for Translational Clinical Protocol Development

Fox Chase Cancer Center recently announced the awardees of the 2018 translational clinical protocol development based on basic and preclinical research results. Translational research disease groups were created with a multidisciplinary group of clinical and research-based faculty, with a focus on...

sarcoma

Cautious Optimism About Olaratumab in Soft-Tissue Sarcoma

The current plethora of drugs in development for oncology is leading to the testing of novel agents in common as well as rare diseases. Targeted therapies have been a focus of great interest in soft-tissue sarcomas, with testing of a variety of oral tyrosine kinase inhibitors leading to the...

sarcoma

Eribulin in Liposarcoma: A Closer Look at the Comparative Data

Sarcoma therapy is a challenge for oncologists. Soft-tissue sarcomas encompass more than 50 different histologies, resulting in limited familiarity of management for many treating physicians. In addition, there have been few available effective therapies. The phase III trial of eribulin (Halavan) ...

Advertisement

Advertisement



Advertisement